Company: RGBP
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0001641172-25-022884
Chunk: 18

Company: Regen BioPharma Inc
Filing Date: 2025-08-11
Form: 10-Q
Item: Part I, Item 2
Chunk 18
---
539       161.75      (48,915         -51.20  
  Rent                                                                               22,500        38.09        22,500        38.09      -                 0.00  
  Total                                                                              99,821       169.00       167,031       282.79      (67,210         -40.24  
  Loss                                                                              (40,756       -69.00      (107,966      -182.79      67,210          -62.25  
  Other                                                                                                                                                          
  Interest                                                                          (24,638       -41.71       (17,554       -29.72      (7,084           40.36  
  Interest                                                                          (12,639       -21.40        (4,339        -7.35      (8,300          191.29  
  Derivative                                                                        (89,259      -151.12          (261        -0.44      (88,998       34098.85  
  Total                                                                            (126,536      -214.23       (22,154       -37.51      (104,382        471.17  
  Net                                                                              (167,292      -283.23      (130,120      -220.30      (37,172          28.57  
  Income                                                                                  -         0.00             -         0.00      -                  n/a  
  Net                                                   $                          (167,292      -283.23      (130,120      -220.30      (37,172          28.57  

Revenues

Revenues
from continuing operations were $59,065 for the three months ended June 30, 2025 and $59,064 for the same period ended 2024. $27,425
of revenue from related parties recognized during the three months ended June 30, 2025 and consisted of anniversary expense receivable
pursuant to a license granted by the Company to Zander Therapeutics, Inc. as did $27,425 for the period ended 2024. $31,640 of revenue
recognized during both of the three months ended June 30, 2025 and 2024 were recognized pursuant to licenses granted to Oncology Pharma,
Inc.

Operating
Expenses

Operating
Expense were $99,824 for the three months ended June 30, 2025 and $ 167,032